You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Gedunin
Gedunin is a naturally occurring Hsp90 inhibitor. Induces Hsp90-dependent client protein degradation and displays antiproliferative activity in vitro (IC50 values are 3.22, 8.84 and 16.8 μM in SKBr3, MCF-7 and CaCo-2 cancer cell lines respectively). Decreases ovarian cancer cell proliferation in vitro and may enhance cisplatin-induced reduction in proliferation (CAT.No 3387). Also exhibits antimalarial activity against P. falciparum (IC50 values are 0.14 and 3.1 μM in parasite development and [3H]-hypoxanthine uptake assays respectively).
Technical Data for Gedunin
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Gedunin
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|ethanol||4.83||10 with gentle warming|
Preparing Stock Solutions for Gedunin
The following data is based on the product molecular weight 482.57. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.07 mL||10.36 mL||20.72 mL|
|5 mM||0.41 mL||2.07 mL||4.14 mL|
|10 mM||0.21 mL||1.04 mL||2.07 mL|
|50 mM||0.04 mL||0.21 mL||0.41 mL|
References for Gedunin
References are publications that support the biological activity of the product.
Uddin et al (2007) Gedunin, a limonoid from Xylocarpus granatum, inhibits the growth of CaCo-2 colon cancer cell line in vitro. Phytother.Res. 21 757 PMID: 17450509
Brandt et al (2008) Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J.Med.Chem. 51 6495 PMID: 18816111
Lee et al (2008) Antimalarial activity of anthothecol derived from Khaya anthotheca (Meliaceae). Phytomedicine 15 533 PMID: 17913482
Kamath et al (2009) Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Int J Gynecol Cancer. 19 1564 PMID: 19955938
If you know of a relevant reference for Gedunin, please let us know.
View Related Products by Product Action
Keywords: Gedunin, Gedunin supplier, Hsp90, inhibitors, inhibits, anticancer, antimalarial, activity, Heat, Shock, Protein, 90, Antimalarials, 3387, Tocris Bioscience
2 Citations for Gedunin
Citations are publications that use Tocris products. Selected citations for Gedunin include:
Yadav et al (2010) Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med (Berl) 88 1243 PMID: 20798912
Rizk et al (2015) Optimization of a Fluorescence-Based Assay for Large-Scale Drug Screening against Babesia and Theileria Parasites. PLoS One 10 e0125276 PMID: 25915529
Do you know of a great paper that uses Gedunin from Tocris? Please let us know.
Reviews for Gedunin
Average Rating: 5 (Based on 1 Review.)
Have you used Gedunin?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cell Cycle and DNA Damage Research Product Guide
This product guide provides a review of the cell cycle and DNA damage research area and lists over 170 products, including research tools for:
- Cell Cycle and Mitosis
- DNA Damage Repair
- Targeted Protein Degradation
- Ubiquitin Proteasome Pathway
- Chemotherapy Targets
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.